Posted by Michael Wonder on 15 Nov 2019
PHARMAC to widen access to the exceptional circumstances process for lamotrigine
15 November 2019 - Patients taking lamotrigine who have concerns about the change can talk with their doctor about remaining on their current brand as PHARMAC has widened the criteria for lamotrigine exceptional circumstances.
“We know that there is a high level of anxiety among people on lamotrigine and their families,” explains Dr Ken Clark, PHARMAC’s medical director.
“We understand the news of the three deaths of patients taking lamotrigine will concern people. We don’t know if this linked to the brand change – and we don’t want people to stop taking their medication out of fear so we’re making it easier for people to stay on their current brand if their doctor believes it is the right thing for them.”
